Pamala Jacobson

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs
    P A Jacobson
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA
    Am J Transplant 12:3326-36. 2012
  2. ncbi Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium
    Pamala A Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 93:624-31. 2012
  3. ncbi Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium
    Pamala A Jacobson
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 91:300-8. 2011
  4. ncbi Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation
    Pamala A Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 91:309-16. 2011
  5. ncbi Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network
    Pamala A Jacobson
    Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 16:421-9. 2010
  6. ncbi Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation
    P Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 44:113-20. 2009
  7. ncbi Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation
    Pamala A Jacobson
    Experiemental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 9:304-11. 2003
  8. ncbi Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT)
    Pamala Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Pharmacol 48:485-94. 2008
  9. ncbi Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation
    Pamala Jacobson
    Department of Experimental and Clinical Pharmacology, WDH 7 189, College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
    Clin Pharmacol Ther 78:486-500. 2005
  10. ncbi Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation
    Pamala Jacobson
    Department of Experimental and Clinical Pharmacology, Weaver Densford Hall 7 189, 308 Harvard Street SE, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Pharmacol 47:6-12. 2007

Collaborators

Detail Information

Publications20

  1. ncbi Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs
    P A Jacobson
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA
    Am J Transplant 12:3326-36. 2012
    ..These data support age-related changes in CNI metabolism. Further studies are needed to determine optimal dosing of CNIs in the elderly...
  2. ncbi Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium
    Pamala A Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 93:624-31. 2012
    ..Clinical factors and elevated CNI levels are associated with nephrotoxicity; however, they do not fully explain the risk. Genetic factors may also predispose individuals to nephrotoxicity...
  3. ncbi Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium
    Pamala A Jacobson
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 91:300-8. 2011
    ..Although its effect is important, it incompletely explains the variability in tacrolimus concentrations and has a relatively low minor allele frequency in whites relative to African Americans (AA)...
  4. ncbi Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation
    Pamala A Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 91:309-16. 2011
    ..Toxicity leads to dose reduction, addition of colony-stimulating factors or erythropoietin, or discontinuation of immunosuppressive therapy. The causes of and risk factors associated with toxicity are unclear...
  5. ncbi Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network
    Pamala A Jacobson
    Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 16:421-9. 2010
    ..The current practice of MMF 1 gm twice daily dosing provides low plasma concentrations in many patients. Higher doses may improve the efficacy of MMF as aGVHD therapy...
  6. ncbi Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation
    P Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 44:113-20. 2009
    ..600 microg(*)h/ml in 87-100% of subjects. There appears to be no significant difference in daily MPA exposure when MMF of 3 g/day is divided into two or three equal doses...
  7. ncbi Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation
    Pamala A Jacobson
    Experiemental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 9:304-11. 2003
    ..Cyclosporine dose requirements in an individual HSCT patient to achieve the desired therapeutic blood target can be estimated using this model...
  8. ncbi Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT)
    Pamala Jacobson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Pharmacol 48:485-94. 2008
    ....
  9. ncbi Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation
    Pamala Jacobson
    Department of Experimental and Clinical Pharmacology, WDH 7 189, College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
    Clin Pharmacol Ther 78:486-500. 2005
    ..Therapeutic monitoring of MPA concentrations with dose adjustment into the therapeutic target appears to be necessary for the most effective use of mycophenolate mofetil...
  10. ncbi Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation
    Pamala Jacobson
    Department of Experimental and Clinical Pharmacology, Weaver Densford Hall 7 189, 308 Harvard Street SE, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Pharmacol 47:6-12. 2007
    ..At time of oral pharmacokinetics, 15 patients (83%) had an AUC(0-12) < 30 microg x h/mL. The initial oral dose should be at least 25% greater than the intravenous dose with follow-up assessment of plasma concentrations...
  11. ncbi Prediction of unbound mycophenolic acid concentrations in patients after hematopoietic cell transplantation
    Jiayin Huang
    Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
    Ther Drug Monit 29:385-90. 2007
    ..Direct measurements of unbound MPA concentrations are necessary in patients requiring unbound concentration monitoring...
  12. ncbi Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation
    Janel Long-Boyle
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Pharmacol 51:679-86. 2011
    ..In patients with adequate renal function, no drug accumulation occurs with consecutive daily dosing...
  13. ncbi High unbound mycophenolic acid concentrations in a hematopoietic cell transplantation patient with sepsis and renal and hepatic dysfunction
    Pamala Jacobson
    Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 11:977-8. 2005
  14. ncbi A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT)
    Juki Ng
    Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN, USA
    Ther Drug Monit 28:394-401. 2006
    ..This approach simplifies AUC0-12 targeting of MPA post hematopoietic cell transplantation...
  15. ncbi Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation
    Ajay Israni
    Department of Nephrology, Hennepin County Medical Center, University of Minnesota, Minneapolis, MN, USA
    Transplantation 90:1401-8. 2010
    ..Therefore, this study investigated single-nucleotide polymorphisms (SNPs) to identify genetic variants associated with AR, accounting for center variation, in a multicenter, prospective, observation study...
  16. ncbi Exposure-response relationships for oxaliplatin-treated colon cancer cells
    Mark N Kirstein
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis 55455, USA
    Anticancer Drugs 19:37-44. 2008
    ..5 h. Cell kill effects are reliant on treatment length; hence, the choice of time exposure must be made with a view to maintaining a balance between the cell kill effects and the clinical feasibility of treating the patient...
  17. ncbi Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations
    Pamala A Jacobson
    Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Pharmacol 45:901-9. 2005
    ..The trend toward higher exposure in the early periods followed by dose reductions suggests that lower initial doses and therapeutic drug monitoring may be necessary...
  18. ncbi Quantitative high-performance liquid chromatography-electrospray ionization tandem mass spectrometry analysis of bis-N7-guanine DNA-DNA cross-links in white blood cells of cancer patients receiving cyclophosphamide therapy
    Bhaskar Malayappan
    Departments of Medicinal Chemistry, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Anal Chem 82:3650-8. 2010
    ..This methodology will be useful for future investigations of the interindividual differences for CPA-induced DNA-DNA cross-linking...
  19. ncbi Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors
    L aurelle A Johnson
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA
    Eur J Clin Pharmacol 64:1047-56. 2008
    ..These enzymes are highly polymorphic resulting in low activity and high expression phenotypes. We hypothesized that polymorphisms of UGT1A9 and 1A8 may alter MPA pharmacokinetics in kidney transplantation...
  20. ncbi Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation
    L aurelle Johnson
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Pharmacol 48:1052-62. 2008
    ..Larger, prospective studies are needed to confirm these findings...